February 14, 2020 / 6:14 AM / 12 days ago

BRIEF-Roche's Tecentriq wins first approval in China for lung cancer

Feb 14 (Reuters) - Roche Holding AG:

* CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTS APPROVAL OF ROCHE'S TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PEOPLE WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

* MARKS FIRST APPROVAL FOR A TECENTRIQ-BASED THERAPY IN CHINA, LESS THAN A YEAR AFTER US FOOD AND DRUG ADMINISTRATION (FDA) AND EUROPEAN MEDICINES AGENCY (EMA) APPROVALS IN THIS INDICATION Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below